Physician profile
Andrew M Ayers
NPI 1326359829
$5,488.83
in general payments reported to CMS, 2019-2025
29 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $305 · 2021: $1,258 · 2022: $1,405 · 2023: $654 · 2024: $588 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,020.16 | 2019-2025 | |
| Philips North America LLC | $572.60 | 2019-2024 | (Br6) Re Entry |
| Amgen INC. | $531.30 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $439.56 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $425.85 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $410.14 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $394.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $339.28 | 2019-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.81 | 2021-2024 | Lifevest |
| Cvrx, INC. | $146.38 | 2021 | |
| Novo Nordisk INC | $108.11 | 2021-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $102.19 | 2019-2024 | |
| Boston Scientific Corporation | $75.99 | 2021-2024 | Watchman Flx |
| Amarin Pharma, INC. | $67.54 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $65.86 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.02 | 2023-2024 | |
| Atricure, INC. | $53.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.30 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $43.69 | 2021-2022 | |
| Abbott Laboratories | $42.03 | 2021 | |
| Esperion Therapeutics, INC. | $38.17 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $37.82 | 2019-2023 | Evkeeza |
| Medtronic, INC. | $37.47 | 2022 | |
| Viiv Healthcare Company | $31.18 | 2024 | Dovato |
| Kiniksa Pharmaceuticals, LTD. | $25.91 | 2022 | |
| Irhythm Technologies, INC. | $19.43 | 2022 | |
| Edwards Lifesciences Corporation | $16.25 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.58 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $5.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.